Personalis, Inc. (Nasdaq: PSNL), a leader in the field of advanced cancer genomics, announced today a collaboration with the prestigious scientific and technological company Merck KGaA, Darmstadt, Germany for research on new response biomarkers and resistance mechanisms to cancer therapies. Merck KGaA, Darmstadt, Germany, will use the latest Immunogenom NeXT ™ immunogenomics platform for tumors to identify and develop clinical biomarkers.
Using innovative tests and analyzes, ImmunoID NeXT provides a complete picture of the genomics and immune microenvironment of each tumor derivable from a single limited sample of tumor tissue. The platform constitutes an end-to-end solution for biomarkers for precision oncology, from discovery to clinical application, which allows the simultaneous analysis of tumor mutations, immunological repertoire, neo-antigens, tumor escape mechanisms, DNA repair pathways, human leukocyte antigens (including typing, loss of heterozygosity and detection of somatic mutations), tumor mutational load (tumor mutational burden, TMB), microsatellite instability (microsatellite instability, MSI), oncovirus, immune checkpoints, gene expression, immune signatures and other advanced biomarkers.
"Merck KGaA, Darmstadt, Germany is a global leader in the development of cancer therapies and we are extremely pleased to be able to work together to identify the next generation of clinical biomarkers for cancer therapies," said Dr. Richard Chen, Scientific Director at Personalis. "We will work together with Merck KGaA, Darmstadt, Germany, to exploit the NeXT platform for the identification of new biomarkers, the analysis of resistance mechanisms to therapies, the stratification of patients, the delineation of a strategy for combined therapies and a categorization exhaustive analysis of tumors at the molecular level in support of precision medicine. "
About Personalis, Inc.
Personalis, Inc. is a growing company specializing in cancer genomics that is transforming the development of next-generation therapies by providing more comprehensive molecular data on each patient's immune response and cancer. The company's NeXT platform was developed to adapt to the complex and ever-changing notions of cancer by providing its customers with biopharmaceutical companies information on all of the approximately 20,000 human genes together with their immune system, derived from a single tissue sample. The Personalis Clinical Laboratory complies with current regulations on good practices (GxP) and is equipped with the CLIA'88 and CAP certifications. For more information, visit personalis.com and follow Personalis on Twitter (@PersonalisInc).
Information on Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, is a prestigious scientific and technological company operating in the healthcare, natural sciences and high-performance materials sectors. Its approximately 56,000 employees are working every day to have a positive impact on the lives of millions of people for a more pleasant and sustainable existence. From the advancement of genetic editing technologies and the discovery of unique ways to treat the most complex diseases to the development of intelligent devices, society is everywhere. In 2018 Merck KGaA, Darmstadt, Germany, generated sales of 14.8 billion euros in 66 different countries.
The company holds global rights to the name and trademark "Merck" internationally. The only exceptions are the United States and Canada, where the commercial divisions of Merck KGaA, Darmstadt, Germany, operate under the names EMD Serono in the health sector, MilliporeSigma in the natural sciences sector and EMD Performance Materials. Since its foundation in 1668, scientific exploration and responsible entrepreneurship have been the cornerstones of the progress made by society in the technological and scientific fields. The founding family is still the majority shareholder of this public company.
The original text of this announcement, written in the source language, is the official version that is authentic. The translations are offered solely for the reader's convenience and must refer to the text in the original language, which is the only legally valid one.
See the original version on businesswire.com: https://www.businesswire.com/news/home/20191119006109/it/
Contact Investor Relations for Personalis:
Caroline Corner
[email protected]
www.westwicke.com
415-202-5678
Media contact for Personalis:
Jennifer Havlek
[email protected]
www.personalis.com
650-752-1300
Permalink: http://www.businesswire.com/news/home/20191119006109/it
Source link
http://www.ansa.it/sito/notizie/economia/business_wire/news/2019-11-20_1202073103.html
Dmca
